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CASE REPORT
Fluconazole Induced Fixed Drug Eruption
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We report on a rare case of fluconazole induced fixed drug 
eruption in a 62-year old female patient. She was referred to 
our department for multiple erythematous itchy maculo-
patches on the face, neck, both upper arms, and trunk area, 
which had occurred over the previous 6 months. Her 
attending physician prescribed fluconazole for treatment of 
onychomycosis. Patch test and oral provocation were 
performed. The patch test showed a negative result; however, 
the result for oral provocation was positive, confirming this 
as a rare case of fluconazole induced fixed drug eruption. To 
the best of our knowledge, this is the first reported case in 
Korean dermatologic literature. (Ann Dermatol 23(S1) S1∼
S3, 2011)
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INTRODUCTION
Fixed drug eruption (FDE) is a distinctive variant of drug 
induced dermatoses with a characteristic recurrence at the 
same sites of the skin or mucous membrane after repeated 
administration of the causative drug
1. FDE is characterized 
by the onset of single or multiple, sharply demarcated, er-
ythematous macules and plaques with or without blister-
ing, often resulting in residual post-inflammatory pigmen-
tation
2. The hands, feet, genitalia, and perianal areas are 
the most favored sites
3. Drugs most frequently implicated 
in fixed drug eruption are antibiotics (trimethoprim-sulfa-
methoxazole, tetracycline, penicillin, and erythromycin), 
followed by NSAID’s (aspirin, mefenamic acids, naprox-
en, and ibuprofen)
2. Fluconazole is used for treatment of 
fungal infection and is known to be relatively safe
3,4. 
Herein we report on a rare case of fluconazole induced 
fixed drug eruption showing a positive response in an oral 
provocation test in a 62-year old woman.
CASE REPORT
A healthy 62-year old woman was administered a single 
150 mg dose of fluconazole for treatment onychomycosis. 
Within 3 hours, she noticed multiple pruritic, oval, swol-
len, erythematous, bright red or dusky red patches meas-
uring 3 to 4 cm with erythematous halos over her face, 
neck, both upper arms, and trunk (Fig. 1). On further in-
quiry, she recalled a history of a similar episode about 6 
months ago, when she had taken fluconazole for treat-
ment of onychomycosis. The patient had no previous his-
tory of any medical conditions, such as allergy or atopic 
dermatitis. She was not taking any regular medications. In 
the laboratory study, except for white blood cell count 
(11,020 cells/mm
3, normal 3,600∼10,200 cells/mm
3), re-
sults of blood sugar, liver function test, and urine analysis, 
Ig E PRIST were all within normal limits. A clinical diag-
nosis of FDE caused by fluconazole was made. A skin bi-
opsy was performed on an erythematous to brownish 
patch on her left upper arm. Histopathological findings re-
vealed an appearance of a fixed drug eruption; an inter-
face dermatitis with dyskeratotic keratinocytes in epi-
dermis, lichenoid lymphocytic infiltration and pigmentary 
incontinence in upper dermis (Fig. 2). She was treated 
with oral prednisolone 10 mg daily for 3 days and 7.5 mg 
daily for 3 days. Oral antihistamine and topical cortico-
steroid ointment were also prescribed. The skin lesion re-CY Kim, et al
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Fig. 1. Oval, swollen, brownish pigmented patches on the ant. Chest (A: Day 3 of eruption, B: 30 minutes after oral provocation).
Fig. 2. (A) Skin biopsy specimen shows basal vacuolated and necrotic keratinocytes with dermal inflammatory cell infiltration and
pigmentary incontinence (H&E, ×100). (B) Necrotic keratinocytes and basal vacuolation are observed and dermal inflammtory cells 
are dominant mononuclear cells (H&E, ×200).
gressed after 10 days; therefore, we performed a patch test 
and an oral challenge test to confirm the relationship be-
tween suspected drug intake and drug interaction 4 weeks 
later. A patch test with fluconazole 0.1%, 1%, and 10% in 
petrolatum placed on the small finn chamber was per-
formed on the previous lesion of the anterior chest; results 
at 48, 72, and 96 hr were all negative. In an oral chal-
lenge test with 50 mg fluconazole (one-third of the ther-
apeutic dose), a lesion reappeared with greater rapidity 
and aggression than before at the same sites after 30 mi-
nutes (Fig. 1B). Herein, we report on a rare case of fluco-
nazole induced FDE diagnosed by an oral challenge test 
and propose addition of fluconazole to the list of drugs 




FDE is a distinctive variant of drug induced dermatoses 
with a characteristic recurrence at the same sites of the 
skin or mucous membrane after repeated administration of 
the causative drug
1. It was first described by Bourns in 
1889, and, 5 years later, it was termed by Brocq as 
“eruption erythemato-pigmentee fixee”
2. Onset of FDE af-
ter drug exposure may vary, from 30 min to 8 to 16 hours. 
On occasion, FDEs may occur with symptoms such as fe-
ver, nausea, diarrhea, abdominal cramps, or con-
junctivitis
2-4. Sites of predilection are the hands, feet, per-
ianal area and, in approximately 50% of cases, genital and 
oral mucous membranes
2. Size and number of lesions 
were found to be greater with recurrence, than with the 
first attack
5,6. 
Histologically, acute fixed drug eruption is characterized 
by marked basal cell hydropic degeneration, with lympho-
cyte tagging along the epidermodermal junction and in-
dividual keratinocyte necrosis. In more advanced lesions, 
subepidermal vesiculation may be a feature
6,7. Infiltration 
of lymphocytes, histiocytes, and neutrophil polymorphs is 
evident in the upper dermis, and eosinophils may some-Fluconazole Induced Fixed Drug Eruption
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times be prominent
6,7. In our case, the histologic examina-
tion revealed a lichenoid infiltrate, basal cell vacuoliza-
tion, and a superficial perivascular lymphocytic infiltrate 
consistent with FDE.
FDE can be caused by many different drugs; however, the 
most frequently implicated medication appears to be anti-
biotics followed by NSAID’s. In our case, there was no 
previous history of allergy, atopic dermatitis, or any medi-
cations other than fluconazole. To the best of our knowl-
edge, regarding antifungal agents, the literature mentions 
only seven cases of FDE caused by fluconazole; one case 
from the use of ketoconazole, and none caused by itraco-
nazole
2,3,5. In Korean dermatologic literature, there have 
been no reported cases of fluconazole induced fixed drug 
eruption.
To confirm the diagnosis of FDE, various skin tests, includ-
ing prick, intradermal, patch, and oral challenge tests us-
ing suspected drugs can be performed
6,8. In our case, we 
performed a patch test and an oral challenge test. 
Respectively, the result of the prick test for FDE may be 
positive in 24% and intradermal skin tests in 67%
9. Patch 
test at the site of a previous lesion was positive in up to 
43%
9. For FDE, sensitivity of skin provocation test is 
variable. If positive results are useful, negative results are 
not an indication that the drug is not a causative agent
3. If 
necessary, an oral provocation test may be performed
3,8. 
In a reported case of fluconazole induced FDE, skin prov-
ocation tests were performed with a preparation of fluco-
nazole 1%, 10% (a dilution of fluconazole parenteral sol-
ution in saline or fluconazole in petrolatum
10) and oral 
provocation tests were performed with 25 mg, 50 mg, and 
150 mg
2. Our patient underwent a patch test and an oral 
challenge test for confirmation 4 weeks later. Patch test 
with fluconazole 0.1%, 1%, and 10% in petrolatum on 
the previous lesion showed only negative results. 
Otherwise, in an oral challenge test with 50 mg flucona-
zole (one-third of the therapeutic dose), a lesion was pro-
voked with greater rapidity and aggression after 30 
minutes.
Fluconazole is used for treatment of fungal infection and is 
known to be relatively safe
3,4. Commonly observed ad-
verse effects due to fluconazole include nausea, vomiting, 
and elevated liver enzyme level. Anaphylactic reaction, 
generalized etanthematous pustulosis, maculopapular rash, 
and FDE have been rarely reported in the literature
2-4,10. 
Although occurrence of fulconazole induced FDE is rare, 
once FDE is induced by fluconazole, the size and the 
number of skin lesions tend to be greater with recurrence 
than with the first attack. Patch test sensitivity is not 100% 
and false negative results can occur, so that results of the 
provocative skin test may not match the clinical 
manifestation. In conclusion, it should be kept in mind 
that use of fluconazole can result in development of fixed 
drug eruption and fluconazole should be prescribed 
carefully. 
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